1. Home
  2. AVTX vs MCHX Comparison

AVTX vs MCHX Comparison

Compare AVTX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avalo Therapeutics Inc.

AVTX

Avalo Therapeutics Inc.

HOLD

Current Price

$14.95

Market Cap

339.9M

Sector

Health Care

ML Signal

HOLD

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

HOLD

Current Price

$1.51

Market Cap

66.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVTX
MCHX
Founded
2011
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
339.9M
66.3M
IPO Year
2015
2003

Fundamental Metrics

Financial Performance
Metric
AVTX
MCHX
Price
$14.95
$1.51
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$36.80
N/A
AVG Volume (30 Days)
745.9K
12.0K
Earning Date
03-23-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
72.07
N/A
EPS
N/A
N/A
Revenue
$27,813,137.00
$90,291,000.00
Revenue This Year
N/A
$9.12
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2312.27
N/A
52 Week Low
$3.39
$1.26
52 Week High
$20.72
$2.30

Technical Indicators

Market Signals
Indicator
AVTX
MCHX
Relative Strength Index (RSI) 48.97 57.39
Support Level $13.38 $1.35
Resistance Level $16.40 $1.60
Average True Range (ATR) 1.08 0.09
MACD -0.09 0.02
Stochastic Oscillator 48.03 85.79

Price Performance

Historical Comparison
AVTX
MCHX

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

Share on Social Networks: